Skip to main content
Clinical Trials/ISRCTN38736987
ISRCTN38736987
Completed
未知

A randomised, double-blind, placebo-controlled trial assessing the safety and efficacy of intracoronary NITRITE infusion during Acute Myocardial Infarction

Barts and The London NHS Trust (UK)0 sites80 target enrollmentJanuary 23, 2013

Overview

Phase
未知
Intervention
Not specified
Conditions
Topic: Cardiovascular
Sponsor
Barts and The London NHS Trust (UK)
Enrollment
80
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Registry
who.int
Start Date
January 23, 2013
End Date
February 10, 2014
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Barts and The London NHS Trust (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients aged at least 18 years, upper age limit 80 years, male and female
  • 2\. Acute ST\-elevation myocardial infarction with ECG showing at least 2 mm of ST segment elevation in 2 or more limb leads or 1mm in 2 or more contiguous chest leads, or new left bundle branch block
  • 3\. Haemodynamically stable
  • 4\. Estimated symptom to balloon or aspiration time \< 6 hours
  • 5\. A signed and dated written informed consent prior to admission to the study
  • 6\. Angiographicallly
  • 6\.1\. Primary Percutaneous Coronary Intervention (PPCI) indicated for revascularisation
  • 6\.2\. Single epicardial artery to be treated
  • 6\.3\. Expected ability to use the over the wire balloon for delivery of nitrite

Exclusion Criteria

  • 1\. Patients already on nitrate Treatment (Nicorandil, ISMN)
  • 2\. Previous history of myocardial infarction (MI) or systolic dysfunction
  • 3\. Previous coronary artery bypass surgery (CABG)
  • 4\. Subjects presenting with cardiogenic shock (SBP \<80 mmHg for \>30 minutes, or requiring inotropes or emergency IntraAortic
  • Balloon Pump (IABP) for hypotension treatment) or cardiopulmonary resuscitation
  • 5\. Current diagnosis of or treatment for malignancy, other than non\-melanoma skin cancer
  • 6\. Current life\-threatening condition other than vascular disease that may prevent a subject completing the study
  • 7\. Use of an investigational device or investigational drug within 30 days or 5 half\-lives (whichever is the longer) preceding the first dose of study medication
  • 8\. Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject?s unwillingness to comply with all study\-related procedures)
  • 9\. Severe acute infection, or significant trauma (burns, fractures)

Outcomes

Primary Outcomes

Not specified

Similar Trials